Each outcome had different predictive factors: baseline HBV DNA and albumin level were predictive factors for virological response, history of interferon therapy and ALT level for HBeAg clearance, and sex and baseline albumin level for ALT normalization. Conclusion:  Long-term add-on ADV treatment was highly effective in LAM-resistant Pifithrin-�� chemical structure chronic hepatitis B patients in terms of virological and biochemical responses. Lower HBV replication and lower albumin level at baseline led to better outcomes. “
“Hepatitis E was suspected for the first time in 1980

during a waterborne epidemic of acute hepatitis in Kashmir, India. In the 30 years since then, a small virus with single-stranded RNA genome has been identified as the cause of this disease and named as hepatitis E virus (HEV). The virus has four genotypes; of these, genotypes 1 and 2 are known to infect only humans, whereas genotypes 3 and 4 primarily infect other mammals, particularly pigs, but occasionally cause human disease. In highly-endemic areas, the disease occurs in epidemic and sporadic forms, caused mainly by infection with genotype 1 or 2 virus, acquired through the fecal-oral route, usually through contaminated water supplies.

LY2157299 in vitro The disease is characterized by particularly severe course and high mortality among pregnant women. In persons with pre-existing chronic liver disease, HEV superinfection can present as acute-on-chronic liver disease. In low-endemic regions, sporadic cases of locally-acquired HEV infection are reported; these are caused mainly by genotype 3 or 4 HEV acquired possibly through zoonotic transmission from pigs, wild boars or deer. In these

areas, chronic infection with genotype 3 HEV, which may progress to liver cirrhosis, has been reported among immunosuppressed persons. Two subunit vaccines containing recombinant truncated capsid proteins of HEV have been shown to be highly effective in preventing the disease; however, these are not yet commercially available. These vaccines should be of particular use in groups that are at high risk of HEV infection and/or of poor outcome. Hepatitis E, caused by hepatitis E virus (HEV), was unknown as a disease entity until 1980. In the initial years after its discovery, it was believed to be 上海皓元医药股份有限公司 a common cause of sporadic and epidemic waterborne acute hepatitis in, and limited to, developing countries, primarily in Asia and Africa. However, in recent years, the host range, geographical distribution and modes of transmission of this virus, and clinical presentations of this infection have been shown to be much broader than were previously believed. In the nearly three decades since the disease was first suspected, besides the identification and characterization of the causative agent, two highly protective subunit vaccines have been developed, setting the stage for its global control. This piece reviews the historical aspects, current status of our understanding and future prospects of research into hepatitis E and HEV.